Janssen Biotech, Inc.

Patrick Branigan

William Strohl

Juan C Almagro

John Wheeler

Mark Tornetta

Colleen Kane

Xuejun P Liu

Susann Taudte

Bruce Randazzo

Jason Ekert

Julianty Angsana

Samuel DePrimo

Susan Flavin

Shu Li

Ernesto Munoz

Juan Carlos Almagro

A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment and the patient achieves higher efficacy than a patient treated with the secukinumab antibody.

Safe and effective method of treating psoriasis with anti-IL-23 specific antibody

The present invention relates to target binding members (e.g., antibodies) that bind a specified epitope of human IL-25. The invention also relates to target binding members (e.g., antibodies) that comprise one or more humanized antibody VL domain sequences and bind IL-25. The invention further relates to compositions comprising target binding members (e.g., antibodies) that bind IL-25, methods of producing such target binding members, and uses of such target binding members for the treatment or prevention of diseases and conditions (e.g., asthma, inflammatory bowel disease).

Humanized IL-25 antibodies

Methods for mediating fibrotic response by modulating IL-25 signaling in fibrocytes are disclosed.

Methods for mediating fibrotic response

Growing community of inventors

Radnor, PA, United States of America

Patrick Branigan